Research-Grade Peptides | 99%+ Purity Verified | US Delivery 2–5 Days
Save 5% with Crypto
SaiyanMed

Your Cart

No products in the cart.

What Is LL-37? Antimicrobial Activity and Immune Signaling in Laboratory Studies

Conceptual peptide motif connected to separate microbial, epithelial–immune, and host-cell assay models.

LL-37 is a 37-residue peptide processed from the human cathelicidin precursor hCAP-18. To interpret LL-37 antimicrobial activity and immune signaling, first identify the organism or cell model, experimental conditions, and measured endpoint. An epithelial–immune co-culture study and an antimicrobial assay address different questions; neither establishes human clinical benefit.[1][2]

LL-37 is a 37-residue human cathelicidin peptide

The name LL-37 reflects its two initial leucine residues and its length of 37 amino-acid residues. It is processed from the C-terminal region of hCAP-18. Ciornei and colleagues identify it as residues 104–140 of that precursor.[1][2]

When comparing reports, distinguish full-length LL-37 from truncated fragments or analogs. The 2005 study examined these separately and reported differences among the tested peptides.[2]

Antimicrobial activity depends on assay conditions

Conceptual radial-diffusion assay layout with separate organism, medium, and serum context symbols.

The accessible abstract of Ciornei et al. (2005) describes radial-diffusion assays involving LL-37 and related fragments against *E. coli*, *P. aeruginosa*, *S. aureus*, and *C. albicans*. It also reports that serum reduced LL-37 antibacterial activity, while two N-terminally truncated fragments were not affected in the same way.[2]

Only the abstract was reviewed for this study. Detailed methods and results—including medium composition, salt concentrations, serum conditions, and exposure conditions—were not verified. The organism list therefore identifies the assay panel; it does not establish equal activity against each organism or supply a transferable potency value.

Readout Organism or cell model Reported finding Conditions and interpretation limit
Antimicrobial activity *E. coli*, *P. aeruginosa*, *S. aureus*, and *C. albicans* in radial-diffusion assays The abstract describes testing LL-37 and related peptide fragments against this panel Abstract-level evidence; detailed medium and salt conditions were not verified. The panel is not evidence of equal activity across organisms. [2]
Serum effect Antibacterial assays comparing LL-37 and fragments Serum reduced LL-37 antibacterial activity; two N-terminally truncated fragments differed Detailed serum conditions were not verified. This does not establish a universal serum-effect threshold. [2]
Immune signaling Direct monocyte exposure versus a polarized Caco-2 epithelial–immune co-culture Below 5 μg/mL, LL-37 did not directly activate monocytes; epithelial co-culture supported activation involving MAPK/ERK and cytokine production An in-vitro model comparison, not in-vivo validation. [1]
Host-cell effects Human erythrocytes and cultured vascular smooth-muscle cells The abstract reports hemolysis and DNA-fragmentation readouts, with differences among peptides Abstract-level evidence; detailed exposure conditions were not verified. These readouts do not establish a universal toxicity threshold. [2]

The antimicrobial, serum, and host-cell entries above come from the Ciornei abstract; the immune-signaling entry comes from the Bogdanov full-text study.[2][1]

How to read the serum example: the reported comparison supports the conclusion that serum reduced LL-37 antibacterial activity in that experimental setup. Because the detailed conditions were not verified, it cannot establish the size of the effect under another medium, serum concentration, or assay format.

A specific salt-dependent result remains unverified from the reviewed Ciornei abstract. Record salt composition and concentration when evaluating an assay, but leave the direction and magnitude of a salt effect unresolved until the relevant methods and results are available.

Immune signaling depends on the cell context

Side-by-side conceptual diagrams of direct monocyte exposure and epithelial-barrier co-culture with monocytes.

Bogdanov et al. (2023) compared direct LL-37 exposure with an in-vitro model containing a polarized Caco-2 epithelial layer and immune cells. Under the tested conditions, concentrations below 5 μg/mL did not directly activate monocytes. In the epithelial-barrier co-culture, the researchers reported monocyte activation involving MAPK/ERK signaling and cytokine production.[1]

How to read this comparison: the known difference is the cellular context—direct exposure versus epithelial–immune co-culture. The result supports a role for epithelial–immune crosstalk in that model. Whether the same response occurs in a living organism remains outside this experiment; the study is not in-vivo validation. Its below-5 μg/mL finding is also specific to the tested conditions, rather than a general activation threshold.

The paper’s discussion refers to earlier salt and serum literature. Those passages should not be presented as antimicrobial measurements performed in its epithelial–immune experiments.[1]

Host-cell effects are model-specific

The Ciornei abstract describes hemolysis in human erythrocytes and DNA fragmentation in cultured vascular smooth-muscle cells. It reports differences among LL-37 and the tested fragments. These are distinct host-cell readouts, not interchangeable measures of a single toxicity threshold.[2]

Because only the abstract was reviewed, no detailed exposure conditions or numerical toxicity limits are assigned here. A comparison with another experiment would require its cell model, peptide identity, exposure conditions, and endpoint.

The 2025 narrative review by Svensson and Nilsson summarizes host-cell cytotoxicity reports across different cell types and experimental contexts. It provides a broader literature overview, rather than an independently measured universal threshold.[3]

A practical evidence checklist

Use the following fields to keep a conclusion aligned with its supporting experiment:

  1. Peptide identity: Full-length LL-37, a truncated fragment, or an analog?
  2. Model: Microbial assay, direct cell exposure, epithelial co-culture, animal experiment, or human study?
  3. Conditions: Which organism or cell type, medium, salt composition, serum conditions, and exposure conditions were reported?
  4. Endpoint: Antimicrobial activity, cytokine production, pathway activation, hemolysis, or DNA fragmentation?
  5. Supported conclusion: What did that endpoint demonstrate in that model, and which information is still missing?

For the Ciornei example, the serum finding can be reported with its abstract-level limitation; a specific salt effect remains unresolved. For the Bogdanov example, the epithelial–monocyte contrast can be reported as an in-vitro finding. Neither example supports a conclusion about human clinical benefit.

Related research: How to Read a Peptide COA: Purity, Identity, Quantity and Red Flags; Peptide Identity Beyond the Product Name: Sequences, Fragments, Modifications, and Salt Forms.

参考来源

  1. Bogdanov et al. (2023): Epithelial-Immune Cell Crosstalk Determines the Activation of Immune Cells In Vitro by the Human Cathelicidin LL-37 at Low Physiological Concentrations
  2. Ciornei et al. (2005): Antimicrobial and Chemoattractant Activity, Lipopolysaccharide Neutralization, Cytotoxicity, and Inhibition by Serum of Analogs of Human Cathelicidin LL-37
  3. Svensson and Nilsson (2025): Narrative review of LL-37 mechanisms and host-cell effects

Research Use Only Disclaimer

This article is for laboratory and analytical research education only. It is not a validated experimental protocol or medical or veterinary advice. The research material discussed is not for administration to humans or animals.